Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is supported by a strong de-risked cardiometabolic franchise, led by plozasiran’s Phase 3 SHASTA-3/4 results showing 79% to 81% median triglyceride reductions at Month 12 and a 78% pooled reduction in adjudicated acute pancreatitis events, with even stronger benefit in prior-pancreatitis patients. These data strengthen the case for a broad sHTG label, support an sNDA before year-end 2026, and provide payer-relevant value with an NNT of 3 in the highest-risk subgroup and an NNT of 24 in the broader pooled analysis. The company’s outlook is further bolstered by Redemplo’s early commercial traction, a recently purchased $215 million priority review voucher, and a pipeline spanning additional cardiometabolic and extra-hepatic RNAi assets.

Arrowhead Pharma is weighed down by the fact that, despite encouraging plozasiran data in SHASTA-3 and SHASTA-4, its RNAi pipeline still faces major clinical, regulatory, and execution risk, including the possibility that future Phase I/II/III studies fail to meet endpoints or reveal safety signals. The company remains exposed to intense competition from better-resourced peers in gene therapy and RNA medicines, while its patents and orphan-drug protections may not fully shield products from rivals or costly IP disputes. Continued cash burn also raises the likelihood of dilutive equity or restrictive debt financing, which could pressure valuation if capital is needed before commercialization gains traction.